白血病化疗药物体外敏感性检测与临床疗效的分析  

AN ANALYSIS OF THE SENSITIVITY ASSAY IN VITRO AND CLINICAL EFFECTS OF CHEMOTHERAPY DRUGS IN ACUTE LEUKEMIA

作　　者：姚海勤[1] 王学文[1] 庄昱洲[1] 应江山[1] 钱晓萍[1] 刘海宁[1] 

机构地区：[1]南京军区南京总医院血液科

出　　处：《肿瘤防治研究》1996年第4期238-241,共4页Cancer Research on Prevention and Treatment

摘　　要：１９例急性白血病，用核仁组成区相关嗜银蛋白（ＡｇＮＯＲ）检测技术，测定白血病细胞对化疗药物体外药敏。参考药敏度选择化疗药物行体内化疗。结果显示：体外药敏与体内疗效总符合率为：８１．８％，阳性符合率为７９．２％，阴性符合率为８５．７％，敏感度为９５．０％，特异性为６１．５％。临床治疗效果，ＡＮＬＬ明显优于ＡＬＬ，完全缓解率分别为８４．６％，３３．３％。该法简便、快速、敏感，对急性白血病的化疗有重要参考价值。The drug sensityivty assay in vitro of leukemic cells from 19 patients with acute leukemia for antileukemic drugs was investigated by the detecting technique of the amount of the argyrophilic proteins associated with nucleolar organiger regions (AgNOR). Application of chemotherapy drugs in the patients refered to the results of drug sensitivity assay in vitro. The results suggested the total corresponding rate of the drug sensitivity in vitro and the clinical chemotherapy response was 81.8%, the positive corresponding rate was 79.2%, the negative corresponding rate was 80.7%, the sensitivity and specificity were 95% and 61.5 %, respectively.The clinical therapy responses in acute non-lymphocylic leukemia were better than those in acute lymphocytic leukemia, complete remission rates were 84.6% and 33.3%, respectively. In conclusion, the AgNORs assay was simple, rapid and sensitive. The method has important value for chemotherapy of acute leukemia.

关 键 词：急性 白血病 药物疗法 

分 类 号：R733.710.5[医药卫生—肿瘤]